ImmunityBio, Inc. (IBRX) SEC Filings & Earnings Calls

Warning about delayed cystectomy risk; metastatic bladder cancer can be lethal.

“The prescribing information includes a warning that delaying cystectomy can lead to the development of metastatic bladder cancer, which can be lethal.” · word for word

Going concern risk due to accumulated deficit and need for additional financing

“We have a history of operating losses, and we expect to continue to incur losses and may never be profitable... We anticipate needing additional financing to fund our operations, complete the commercialization of our approved product, including for efforts to obtain approval for additional indications, conduct clinical trials, and develop and commercialize o” · word for word

Dependence on single approved product (ANKTIVA) and BCG supply

“We are substantially dependent on the successful commercialization of our approved product and the success and regulatory approval of our other product candidates. If we are unable to successfully commercialize our approved product... our business will be materially harmed.” · word for word

Significant dilution risk from warrants, convertible notes, and CVRs

“Conversion of related-party promissory notes, exercise of outstanding warrants and options to purchase our common stock, the achievement of the milestone under our outstanding CVRs, and potential additional equity issuances may dilute the ownership interest of existing stockholders or may otherwise depress the price of our common stock.” · word for word

Revenue interest obligation (RIPA) reduces cash flow from product sales

“Oberland has the right to receive quarterly Revenue Interest Payments from us based on, among other things, our worldwide net sales, excluding those in China, which are tiered payments ranging from 5.625% to 12.50%” · word for word

Regulatory approval uncertainty for new indications

“In May 2026, we announced that the FDA had accepted for review the sBLA for ANKTIVA... There can be no assurance that the FDA will ultimately approve our sBLA.” · word for word

High net loss driven by non-cash fair value changes and increased R&D/SG&A spending; reliance on continued commercial success and pipeline advancement.

“Net loss increased to $230.4M due to non-cash changes in fair value of convertible note and warrant liabilities.”

Regulatory approval in UAE is positive but does not guarantee commercial success; revenue impact uncertain.

“No revenue guidance or sales projections provided; approval is a milestone but commercial uptake depends on pricing, reimbursement, and physician adoption.”

Dependence on FDA approval for commercialization; no revenue until approval.

“No payment due prior to FDA approval; all vials for regulatory submission at no cost.”

High R&D and SG&A spending growth may pressure margins if revenue growth slows.

“R&D up 41%, SG&A up 40% YoY.”

Dependence on ANKTIVA for revenue; regulatory and commercial execution risks.

“Revenue concentrated in single product ANKTIVA.”

Going concern risk

“we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support.” · word for word

Dependence on related-party financing

“Related-party convertible note payable, at fair value $678,386k; Interest expense – related party $14,559k” · word for word

Significant non-cash losses from warrant and convertible note revaluation

“Change in fair value of warrant liabilities (295,413); Change in fair value of related-party convertible note (236,625)” · word for word

Concentration of revenue from single product (ANKTIVA)

“Product revenue, net $44,167 $16,509 (all from ANKTIVA)”

Litigation risk from Beike arbitration

“Beike is asserting a claim for breach of contract under the license agreement.” · word for word

Dependence on single product ANKTIVA

“Revenue is entirely from ANKTIVA; pipeline products are in clinical stages.”

Significant net loss and negative cash flow

“Net loss of $351.5M in 2025; Adjusted EBITDA of -$189.7M.”

Related-party debt and governance concentration

“Dr. Soon-Shiong and affiliates own ~65.5% of shares; $505M convertible note from related party.”

Preliminary results subject to adjustment; final Q1 2026 10-Q may differ.

“These preliminary estimates may differ materially from the actual results that will be reflected in the Company’s consolidated financial statements for the fiscal quarter ended March 31, 2026.” · word for word

FDA regulatory scrutiny on promotional practices; potential for further enforcement if corrective actions insufficient.

“FDA Warning Letter regarding a television advertisement and a podcast; company implementing corrective actions including expanded promotional review protocols, executive training, and external regulatory oversight.”

High cost of capital: revenue interest sale at elevated tiered rates (up to 12.5%) significantly dilutes future product revenue, indicating severe cash constraints.

“Tiered rate increased to 5.625%-12.5% from 4.5%-10%; cumulative purchaser payments target $375M by 2029; 195% cap on total payments.”

Related party concentration: $480M convertible note held by Executive Chairman affiliate creates governance and refinancing risk.

“Nant Capital, LLC, affiliated with Dr. Patrick Soon-Shiong, holds $480M convertible note after partial conversion.”

Regulatory Approval Risk for New Indications

“Our ability to obtain incremental approvals for ANKTIVA for new indications, including, without limitation, in BCG-unresponsive NMIBC with papillary tumors and NSCLC from the FDA or clearances or approvals from international regulatory agencies for the treatment of patients with NMIBC, NSCLC or other indications.” · word for word

Financing Risk

“Our ability to obtain additional financing to fund our operations and advance the commercialization of our approved product and the development and commercialization of our other product candidates.” · word for word

Clinical Trial Risk

“Our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates, which would prevent or delay regulatory approval and commercialization of other product candidates.” · word for word

Dependence on single product ANKTIVA for revenue; any regulatory or commercial setback could materially impact results.

“All revenue derived from ANKTIVA; no other approved products mentioned.”

Regulatory approval risk for label expansion; FDA pathway for lung cancer not yet secured.

“Discussions with U.S. FDA regarding an accelerated approval pathway also planned for 2026.”

Commercial execution risk in new markets (EU, KSA) with partnerships.

“Distribution partnerships with Accord Healthcare and BioPharma & Cigalah; new subsidiaries established.”

Commercial success depends on market adoption and reimbursement.

“Authorization received; commercial launch pending.”

Potential dilution from convertible note conversion; related party transaction with executive chairman.

“Convertible Promissory Note in outstanding principal amount of $505.0 million; Holder is Nant Capital, LLC, an entity affiliated with Dr. Patrick Soon-Shiong.”

Preliminary results subject to adjustment; reliance on single product ANKTIVA.

“These amounts reflect the Company's preliminary estimates based solely upon information available to it as of the date of this press release... may differ materially from the actual results.” · word for word

Regulatory approval in Saudi Arabia is positive but commercial uptake and reimbursement remain uncertain.

“Approval is accelerated; no revenue or sales guidance provided; market size not quantified.”

Significant dilution risk from up to $460M in additional equity issuance and increased authorized share count, potentially pressuring stock price.

“Amendment to Sale Agreement authorizes additional $459,972,480 of Shares; authorized shares increased by 300 million.”

No material risk; routine board appointment with standard compensation.

“Standard director compensation policy; no unusual arrangements.”

Regulatory uncertainty; no details on updates

“regulatory updates announced; details not provided”

Net loss still significant despite revenue growth.

“Net loss attributable to ImmunityBio common stockholders was $67.3 million during the three months ended September 30, 2025” · word for word

R&D and SG&A expenses increasing.

“Research and development (R&D) expense increased $0.8 million to $51.2 million... Selling, general and administrative (SG&A) expense increased $0.4 million to $36.3 million” · word for word

Going concern risk

“As a result of continuing anticipated operating cash outflows as we commercialize our approved product and accelerate our development efforts, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support.” · word for word

Customer concentration

“During the nine months ended September 30, 2025, approximately 96% of our total gross revenue was from our top four customers, which accounted for 41%, 20%, 18% and 17% of our total revenue, respectively.” · word for word

Related-party risk

“Related-party convertible note payable, at fair value $500,804 (September 30, 2025) vs $461,877 (December 31, 2024)” · word for word